The nvax stock price forecast may benefit from sector-wide sentiment improvements if health policy developments favor vaccine innovation incentives. Shares of Novavax rose nearly 13% yesterday, attributable to this transition. A pharma giant like Sanofi, which already has a well-built distribution and commercial supply chain across the globe, is likely better placed to market Nuvaxovid than the company for the current vaccination season. Biotechnology company Novavax released its second-quarter results for 2025. The latest nvax stock price forecast suggests potential short-term volatility as Novavax faces earnings-driven sentiment shifts. Analysts note NVAX recently hovered near $4.50, with technical resistance at $5.
